Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2025-12-26 @ 3:03 AM
Study NCT ID:
NCT05498220
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-02
First Post:
2022-08-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-17
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-11-07
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-09
First Submit QC Date:
None
Study First Post Date:
2022-08-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-25
Last Update Post Date:
2025-09-02
Last Update Post Date Type:
ESTIMATED